369 related articles for article (PubMed ID: 24917306)
1. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
2. Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
Sivalingam VN; Kitson S; McVey R; Roberts C; Pemberton P; Gilmour K; Ali S; Renehan AG; Kitchener HC; Crosbie EJ
Br J Cancer; 2016 Feb; 114(3):281-9. PubMed ID: 26794276
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
Soliman PT; Zhang Q; Broaddus RR; Westin SN; Iglesias D; Munsell MF; Schmandt R; Yates M; Ramondetta L; Lu KH
Gynecol Oncol; 2016 Dec; 143(3):466-471. PubMed ID: 27745917
[TBL] [Abstract][Full Text] [Related]
4. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression.
Dong L; Zhou Q; Zhang Z; Zhu Y; Duan T; Feng Y
J Obstet Gynaecol Res; 2012 Aug; 38(8):1077-85. PubMed ID: 22540333
[TBL] [Abstract][Full Text] [Related]
5. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Hosono K; Endo H; Takahashi H; Sugiyama M; Uchiyama T; Suzuki K; Nozaki Y; Yoneda K; Fujita K; Yoneda M; Inamori M; Tomatsu A; Chihara T; Shimpo K; Nakagama H; Nakajima A
Mol Carcinog; 2010 Jul; 49(7):662-71. PubMed ID: 20564343
[TBL] [Abstract][Full Text] [Related]
6. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.
Laskov I; Drudi L; Beauchamp MC; Yasmeen A; Ferenczy A; Pollak M; Gotlieb WH
Gynecol Oncol; 2014 Sep; 134(3):607-14. PubMed ID: 24972190
[TBL] [Abstract][Full Text] [Related]
7. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Dowling RJ; Niraula S; Chang MC; Done SJ; Ennis M; McCready DR; Leong WL; Escallon JM; Reedijk M; Goodwin PJ; Stambolic V
Breast Cancer Res; 2015 Mar; 17(1):32. PubMed ID: 25849721
[TBL] [Abstract][Full Text] [Related]
8. Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers.
Bateman NW; Teng PN; Hope E; Hood BL; Oliver J; Ao W; Zhou M; Wang G; Tommarello D; Wilson K; Litzy T; Conrads KA; Hamilton CA; Darcy KM; Casablanca Y; Maxwell GL; Bae-Jump V; Conrads TP
Cancer Med; 2020 Feb; 9(3):1092-1103. PubMed ID: 31808620
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].
Bershteĭn LM; Maksimov SIa; Danilova MA; Gershfel'd ÉD; Boiarkina MP; Khadzhimba AS; Kovalevskiĭ AIu; Turkevich EA; Meshkova IE
Vopr Onkol; 2011; 57(6):737-41. PubMed ID: 22416390
[TBL] [Abstract][Full Text] [Related]
10. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Bonanni B; Puntoni M; Cazzaniga M; Pruneri G; Serrano D; Guerrieri-Gonzaga A; Gennari A; Trabacca MS; Galimberti V; Veronesi P; Johansson H; Aristarco V; Bassi F; Luini A; Lazzeroni M; Varricchio C; Viale G; Bruzzi P; Decensi A
J Clin Oncol; 2012 Jul; 30(21):2593-600. PubMed ID: 22564993
[TBL] [Abstract][Full Text] [Related]
11. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway.
Li B; Takeda T; Tsuiji K; Kondo A; Kitamura M; Wong TF; Yaegashi N
Gynecol Endocrinol; 2013 Jan; 29(1):87-90. PubMed ID: 22835064
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
13. Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells.
Tosca L; Ramé C; Chabrolle C; Tesseraud S; Dupont J
Reproduction; 2010 Feb; 139(2):409-18. PubMed ID: 19906888
[TBL] [Abstract][Full Text] [Related]
14. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
15. Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer.
Cai D; Sun H; Qi Y; Zhao X; Feng M; Wu X
Int J Gynecol Cancer; 2016 Nov; 26(9):1667-1672. PubMed ID: 27654259
[TBL] [Abstract][Full Text] [Related]
16. Metformin: taking away the candy for cancer?
Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Hanawa S; Mitsuhashi A; Shozu M
PLoS One; 2018; 13(2):e0192759. PubMed ID: 29444159
[TBL] [Abstract][Full Text] [Related]
18. Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients.
Carvajal R; Rosas C; Kohan K; Gabler F; Vantman D; Romero C; Vega M
Hum Reprod; 2013 Aug; 28(8):2235-44. PubMed ID: 23595973
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
Schuler KM; Rambally BS; DiFurio MJ; Sampey BP; Gehrig PA; Makowski L; Bae-Jump VL
Cancer Med; 2015 Feb; 4(2):161-73. PubMed ID: 25417601
[TBL] [Abstract][Full Text] [Related]
20. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
